New Leaf Venture Partners is a leading healthcare technology focused venture capital firm with a team of senior partners that has been successfully investing together for nearly 2 decades. The New Leaf team has invested over $1.6 billion in 126 healthcare technology companies within 6 distinct funds since 1995. NLV focuses on investments in the biopharmaceutical, information convergence (HCIT), medical device, and biological research tools & infrastructure sectors. Our goal is to generate outstanding returns for our limited partners by building strong companies that are developing clinically important and commercially attractive products.

Across all sectors and stages, the New Leaf team is focused on building value in companies by creating strong management teams and then collaborating with them to develop, manage, and execute capital efficient business plans. Investment decisions are primarily driven by a fundamental assessment of the risks in the underlying development programs (i.e., technical, clinical, regulatory, financial, and commercial risks). Through these efforts, New Leaf has earned a reputation as a value-added investor and has created consistently top-performing portfolios of healthcare technology investments.

The NLV investment team has deep operating experience and medical and technical expertise as well as broad networks of noteworthy advisors and consultants across academia, industry, and clinical medicine which are integral to our active investment approach. This allows us to work closely with founders, management, and co-investors on identifying and achieving optimal paths to value creation and exit.

NLV Partners has offices in New York and San Mateo, California. We are currently making new investments through New Leaf Ventures II, a $450 million fund, which started its investing cycle in mid-2008.

Spiracur’s SNaP Wound Care System Awarded Coverage by Health Care Services Corporation

MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome

Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox

Chimerix's Brincidofovir Selected for Two Oral Presentations Highlighting Resistance Data in CMV and Adenovirus at ICAAC

TigerText Growth Accelerates in First Half of 2014 as Message Volume Surges 750%